The glossy before and after transformations dominating social media rarely tell the whole story. While GLP-1 medicines have helped many people manage obesity and type 2 diabetes, some former users are now sharing personal accounts of bone loss, ovarian cysts and hospital visits that have received far less attention.
Their experiences do not prove the medicines caused these conditions, but they highlight concerns that deserve careful discussion between patients and healthcare professionals. As demand for GLP-1 treatments continues to grow, experts say understanding both the benefits and the risks is more important than ever.
Stories Beyond the Before and After
Weight loss videos featuring medicines such as Ozempic, Wegovy, Mounjaro and Zepbound have become some of the most watched health content online. Many posts celebrate dramatic physical changes, reduced appetite and rapid weight loss without spending much time discussing possible complications.
At the same time, a growing number of former users are posting their own experiences after stopping treatment. These stories include severe digestive problems, unexpected hospital visits and concerns that they believe were not fully explained before beginning the medication, although individual experiences vary and do not establish a direct cause.
Health Stories Spark Concern
One former user said a routine medical check after coming off Ozempic revealed significant bone density loss, including osteoporosis and osteopenia. She described feeling shocked because she had only used the medication for around a year and had not expected those findings.
Another woman shared her experience after taking a copper peptide, saying she later developed severe pelvic pain, ovarian cysts and signs of endometriosis. She stressed that she believed there was a connection after researching possible hormonal effects herself, but her experience remains a personal account rather than scientific proof.
Doctors Warn of Known Risks
Medical professionals already recognise that GLP-1 medicines can cause side effects including nausea, vomiting, diarrhoea and constipation. Research has also linked these medicines with uncommon but more serious conditions such as pancreatitis, bowel obstruction and stomach paralysis, although these complications remain relatively rare.
@ditto.daily GLP1s are being talked about everywhere regarding weight, but they actually have many functions beyond that! Directly in our brain, our reproductive system, and in reducing inflammation. Research harnessing them for women’s health conditions like endometriosis and PCOS is really promising, and nowhere near enough people are talking about this potential use for them. Alongside this, we hear many positive anecdotal stories. 🔍The research in endometriosis is early stage, while in PCOS it is much more advanced. ⚠️For both, more trials are needed to understand how they can be best used in a way that is both safe and effective. Hoteit BH et al. The dual impact of GLP1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials. Ther Adv Endocrinol Metab. 2025 Krasnyi et al. The Levels of Ghrelin, Glucagon, Visfatin and Glp1 Are Decreased in the Peritoneal Fluid of Women with Endometriosis along with the Increased Expression of the CD10 Protease by the Macrophages. International journal of molecular sciences. 2022 Mehdi et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in immunology. 2023 Sola-Leyva et al. The hidden impact of GLP1 receptor agonists on endometrial receptivity and implantation. Acta obstetricia et gynecologica Scandinavica.2025 #pcos #endometriosis
♬ Self Aware - Temper City
Health experts continue to emphasise that these medicines were developed for specific medical purposes and should only be used under proper supervision. Decisions about starting or stopping treatment should always be made with a qualified healthcare provider who can weigh individual risks and benefits.
Legal Cases Raise Fresh Questions
Beyond personal stories, social media creators have also pointed to lawsuits involving GLP-1 manufacturers. Some legal complaints allege that patients were not adequately warned about certain risks, although the companies involved have denied wrongdoing and the cases have not been fully resolved in court.
The online discussion has also expanded to include claims about long term metabolic changes and other lasting health effects. Many of these statements are opinions or personal interpretations rather than established medical conclusions, making it important to separate verified evidence from individual experiences.
Demand Outpaces Answers
GLP-1 medicines have become one of the fastest growing areas in modern healthcare. Their popularity has been driven by impressive clinical results for weight management and diabetes treatment, as well as widespread attention across social media and celebrity culture.
That rapid growth has also encouraged more public discussion about safety, especially as larger numbers of people use the medicines for longer periods. Researchers continue to study potential long term effects, while regulators monitor new safety information as more evidence becomes available.
Patients Need the Full Picture
The stories shared by former users do not erase the documented benefits that GLP-1 medicines provide for many patients. For people with obesity or type 2 diabetes, these treatments can significantly improve health when prescribed appropriately and monitored carefully.
At the same time, the experiences circulating online remind patients to ask detailed questions before beginning treatment and to report any unusual symptoms promptly.
The most informed decisions come from balancing medical evidence with open conversations about both the potential benefits and the possible risks, rather than relying only on dramatic before and after videos.
